POSTBIOTICS AS FACTORS AGAINST DISEASES ALONG METABOLIC AXES

Abstract

The review represents an analysis of recent year publications in connection with preventive and therapeutic use of postbiotics (PB). Postbiotics are widely used as immunomodulators, anti-inflammatory agents, protectors and the normalizers of metabolism of the open cavity mucosal biotopes, liver, brain and other organs, tissues and innate immunity cell populations that co-function to intestinal microbial metabolites as a network (cofunction within a number of metabolic axes “intestine-other locations”). They act in combination with other effectors as auxiliary agents prolonging the effect of drugs and supporting them. Prophylactic and therapeutic uses of PB are directed against groups of intestinal infection diseases, hepatitis, tumors, neurodegenerative brain disorders, other metabolic disorders and pathologies. New aspects of research of PB include the study and application of recognizing and binding therapeutic PB according to and in connection with a network of “Probiotic lectins—Glycoconjugates” interactions. The data indicate the prospects of a search and application of the new groups and combinations of PB directed at glycoconjugate exposed targets in accompanying and supportive therapy. Probiotic bifidobacteria, lactobacilli, baker’s yeast and probiotic lectins are perspective resources of synergistic sets of metabolite-cellular PB against diseases, pathologies and groups of infections.